Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435849 | 0.90 | SSTR1 (0.38) | LOXL2HRH1TAAR1CYP1A2KDM4E | |
| SCHEMBL6596072 | 0.85 | KMT2A (0.40) | TAAR1CYP1A2KDM4EALDH1A1KMT2A | |
| SCHEMBL30670275 | 0.85 | MTOR (0.38) | CYP1A2KDM4EALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7340468 | 0.84 | KMT2A (0.39) | TAAR1CYP1A2KDM4EALDH1A1KMT2A | |
| SCHEMBL28128066 | 0.83 | MAOB (0.44) | TAAR1KDM4EALDH1A1KMT2AHTR2A | |
| SCHEMBL600053 | 0.82 | TAAR1 (0.50) | HRH1TAAR1KDM4EKMT2AMEN1 | |
| SCHEMBL2093913 | 0.82 | MTOR (0.36) | CYP1A2KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL27871635 | 0.82 | KCNH2 (0.50) | TAAR1CYP1A2NPC1RAB9ACXCR2 | |
| SCHEMBL535052 | 0.82 | PDE5A (0.44) | KDM4EALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL27641126 | 0.82 | ALPL (0.41) | CYP1A2KDM4EKMT2AMTORADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | claimed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | claimed |
| EP-2167096-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | Cypress Bioscience, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. (US) | 2009-11-05 | — | — | US | claimed |
| WO-2008157094-A1 | IMPROVING THE TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCE, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | OBECURE LTD. (IL) | 2010-08-12 | — | — | US | disclosed |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | CYPRESS BIOSCIENCES, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2006113557-A2 | GPCR MODULATORS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2006-10-26 | — | — | WO | disclosed |
| CN-1713907-A | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE (CH) | 2005-12-28 | — | — | CN | disclosed |
| US-20050096348-A1 | DPP IV inhibitors | BOEHRINGER MARKUS (CH) | 2005-05-05 | — | — | US | disclosed |
| US-6861440-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275562-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR2C, HTR3A | LOXL2 2846/4885HRH1 39/4885TAAR1 186/4885 |
| US-20100160294-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | LOXL2 3012/4885HRH1 29/4885TAAR1 185/4885 |
| US-20100204205-A1 | TOLERABILITY OF MIRTAZAPINE AND A SECOND ACTIVE AGENT BY USING THEM IN COMBINATION | HTR2A, HTR3A, HTR2C | LOXL2 3756/4885HRH1 16/4885TAAR1 196/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | LOXL2 4428/4885HRH1 1777/4885TAAR1 3278/4885 |
| US-20050096348-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | LOXL2 4585/4885HRH1 1829/4885TAAR1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.